Literature DB >> 23992536

Human rhinovirus species C infection in young children with acute wheeze is associated with increased acute respiratory hospital admissions.

Desmond W Cox1, Joelene Bizzintino, Giovanni Ferrari, Siew Kim Khoo, Guicheng Zhang, Siobhan Whelan, Wai Ming Lee, Yury A Bochkov, Gary C Geelhoed, Jack Goldblatt, James E Gern, Ingrid A Laing, Peter N Le Souëf.   

Abstract

RATIONALE: Human rhinovirus species C (HRV-C) is the most common cause of acute wheezing exacerbations in young children presenting to hospital, but its impact on subsequent respiratory illnesses has not been defined.
OBJECTIVES: To determine whether acute wheezing exacerbations due to HRV-C are associated with increased hospital attendances due to acute respiratory illnesses (ARIs).
METHODS: Clinical information and nasal samples were collected prospectively from 197 children less than 5 years of age, presenting to hospital with an acute wheezing episode. Information on hospital attendances with an ARI before and after recruitment was subsequently obtained.
MEASUREMENTS AND MAIN RESULTS: HRV was the most common virus identified at recruitment (n = 135 [68.5%]). From the 120 (88.9%) samples that underwent typing, HRV-C was the most common HRV species identified, present in 81 (67.5%) samples. Children with an HRV-related wheezing illness had an increased risk of readmission with an ARI (relative risk, 3.44; 95% confidence interval, 1.17-10.17; P = 0.03) compared with those infected with any other virus. HRV-C, compared with any other virus, was associated with an increased risk of a respiratory hospital admission before (49.4% vs. 27.3%, respectively; P = 0.004) and within 12 months (34.6% vs. 17.0%; P = 0.01) of recruitment. Risk for subsequent ARI admissions was further increased in atopic subjects (relative risk, 6.82; 95% confidence interval, 2.16-21.55; P = 0.001). Admission risks were not increased for other HRV species.
CONCLUSIONS: HRV-C-related wheezing illnesses were associated with an increased risk of prior and subsequent hospital respiratory admissions. These associations are consistent with HRV-C causing recurrent severe wheezing illnesses in children who are more susceptible to ARIs.

Entities:  

Mesh:

Year:  2013        PMID: 23992536      PMCID: PMC5447292          DOI: 10.1164/rccm.201303-0498OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  33 in total

1.  Acute asthma in children: Relationships among CD14 and CC16 genotypes, plasma levels, and severity.

Authors:  Andrew C Martin; Ingrid A Laing; Siew-Kim Khoo; Guicheng Zhang; Kristina Rueter; Laurel Teoh; Shahir Taheri; Catherine M Hayden; Gary C Geelhoed; Jack Goldblatt; Peter N LeSouëf
Journal:  Am J Respir Crit Care Med       Date:  2005-12-30       Impact factor: 21.405

2.  Molecular detection and identification of enteroviruses using enzymatic amplification and nucleic acid hybridization.

Authors:  N M Chapman; S Tracy; C J Gauntt; U Fortmueller
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

3.  Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.

Authors:  N Sigurs; R Bjarnason; F Sigurbergsson; B Kjellman
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

4.  Characterization of two newly recognized rhinovirus serotypes of human origin.

Authors:  A Z Kapikian; M A Mufson; H D James; A R Kalica; H H Bloom; R M Chanock
Journal:  Proc Soc Exp Biol Med       Date:  1966 Aug-Sep

Review 5.  Rhinovirus-induced bronchiolitis and asthma development.

Authors:  Tuomas Jartti; Matti Korppi
Journal:  Pediatr Allergy Immunol       Date:  2011-06       Impact factor: 6.377

6.  Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years.

Authors:  R T Stein; D Sherrill; W J Morgan; C J Holberg; M Halonen; L M Taussig; A L Wright; F D Martinez
Journal:  Lancet       Date:  1999-08-14       Impact factor: 79.321

7.  Beta2-adrenoceptor polymorphisms predict response to beta2-agonists in children with acute asthma.

Authors:  Andrew C Martin; Guicheng Zhang; Kristina Rueter; Siew-Kim Khoo; Joelene Bizzintino; Catherine M Hayden; Gary C Geelhoed; Jack Goldblatt; Ingrid A Laing; Peter N Le Souëf
Journal:  J Asthma       Date:  2008-06       Impact factor: 2.515

8.  High-throughput, sensitive, and accurate multiplex PCR-microsphere flow cytometry system for large-scale comprehensive detection of respiratory viruses.

Authors:  Wai-Ming Lee; Kris Grindle; Tressa Pappas; David J Marshall; Michael J Moser; Edward L Beaty; Peter A Shult; James R Prudent; James E Gern
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

9.  Rhinovirus-induced wheezing in infancy--the first sign of childhood asthma?

Authors:  Anne Kotaniemi-Syrjänen; Raija Vainionpää; Tiina M Reijonen; Matti Waris; Kaj Korhonen; Matti Korppi
Journal:  J Allergy Clin Immunol       Date:  2003-01       Impact factor: 10.793

10.  High prevalence of human rhinovirus C infection in Thai children with acute lower respiratory tract disease.

Authors:  Piyada Linsuwanon; Sunchai Payungporn; Rujipat Samransamruajkit; Nawarat Posuwan; Jarika Makkoch; Apiradee Theanboonlers; Yong Poovorawan
Journal:  J Infect       Date:  2009-06-06       Impact factor: 6.072

View more
  76 in total

1.  Exacerbation-Prone Asthma.

Authors:  Loren C Denlinger; Peter Heymann; Rene Lutter; James E Gern
Journal:  J Allergy Clin Immunol Pract       Date:  2019-11-22

2.  Production, purification, and capsid stability of rhinovirus C types.

Authors:  Theodor F Griggs; Yury A Bochkov; Kazuyuki Nakagome; Ann C Palmenberg; James E Gern
Journal:  J Virol Methods       Date:  2015-02-24       Impact factor: 2.014

3.  Association of Rhinovirus C Bronchiolitis and Immunoglobulin E Sensitization During Infancy With Development of Recurrent Wheeze.

Authors:  Kohei Hasegawa; Jonathan M Mansbach; Yury A Bochkov; James E Gern; Pedro A Piedra; Cindy S Bauer; Stephen J Teach; Susan Wu; Ashley F Sullivan; Carlos A Camargo
Journal:  JAMA Pediatr       Date:  2019-06-01       Impact factor: 16.193

4.  Human rhinovirus, wheezing illness, and the primary prevention of childhood asthma.

Authors:  Carlos A Camargo
Journal:  Am J Respir Crit Care Med       Date:  2013-12-01       Impact factor: 21.405

5.  Single-Cell Tracking Reveals a Role for Pre-Existing CCR5+ Memory Th1 Cells in the Control of Rhinovirus-A39 After Experimental Challenge in Humans.

Authors:  Lyndsey M Muehling; Ronald B Turner; Kenneth B Brown; Paul W Wright; James T Patrie; Sampo J Lahtinen; Markus J Lehtinen; William W Kwok; Judith A Woodfolk
Journal:  J Infect Dis       Date:  2018-01-17       Impact factor: 5.226

Review 6.  Early-life viral infections and the development of asthma: a target for asthma prevention?

Authors:  Daniel J Jackson
Journal:  Curr Opin Allergy Clin Immunol       Date:  2014-04

Review 7.  Infection in severe asthma exacerbations and critical asthma syndrome.

Authors:  Christian E Sandrock; Andrew Norris
Journal:  Clin Rev Allergy Immunol       Date:  2015-02       Impact factor: 8.667

8.  Sex-specific risk factors for childhood wheeze and longitudinal phenotypes of wheeze.

Authors:  Sze Man Tse; Sheryl L Rifas-Shiman; Brent A Coull; Augusto A Litonjua; Emily Oken; Diane R Gold
Journal:  J Allergy Clin Immunol       Date:  2016-04-27       Impact factor: 10.793

Review 9.  The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma.

Authors:  Richard Hewitt; Hugo Farne; Andrew Ritchie; Emma Luke; Sebastian L Johnston; Patrick Mallia
Journal:  Ther Adv Respir Dis       Date:  2015-11-26       Impact factor: 4.031

10.  Multicenter study of viral etiology and relapse in hospitalized children with bronchiolitis.

Authors:  Kohei Hasegawa; Jonathan M Mansbach; Stephen J Teach; Erin S Fisher; Daniel Hershey; Joyce Y Koh; Sunday Clark; Pedro A Piedra; Ashley F Sullivan; Carlos A Camargo
Journal:  Pediatr Infect Dis J       Date:  2014-08       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.